IPH6101/SAR'579 (SAR443579) is the first NKp46/CD16-based NK cell engager (NKCE) using Innate’s proprietary multispecific antibody format ANKET®. It has shown anti-tumor activity in pre-clinical models, including supporting pharmacokinetic/pharmacodynamic (PK/PD) and safety data in non-human primate studies, leading to its selection as a drug candidate for development.

It is part of a previously announced research collaboration and licensing agreement with Sanofi, under which the companies collaborate on the development of innovative multi-specific antibody formats engaging NK cells through the activating receptors NKp46 and CD16 to kill tumor cells.

About ANKET®

ANKET® (Antibody-based NK cell Engager Therapeutics) is Innate's proprietary platform for developing next-generation, multi-specific natural killer (NK) cell engagers to treat certain types of cancer. 

In pre-clinical studies, Innate's tri- and tetra-specific ANKET® technologies promote potent NK cell activation, cytotoxicity and efficient control of tumor growth in pre-clinical models. This versatile fit-for-purpose technology is creating an entirely new class of molecules to induce synthetic immunity against cancer.  

Learn more about our ANKET® technology


IPH6101/SAR'579 is progressing to Phase 2 dose expansion part of the clinical trial, in patients with relapsed or refractory acute myeloid leukemia (R/R AML), B-cell acute lymphoblastic leukemia (B-ALL) or high risk-myelodysplastic syndrome (HR-MDS), sponsored by Sanofi.

•    The purpose of the dose escalation and dose expansion study is to evaluate the safety, pharmacokinetics, pharmacodynamics and initial clinical activity of IPH6101/SAR'579 in various CD123-expressing hematological malignancies. 

Under the terms of the license agreement, Sanofi is responsible for the development, manufacturing and commercialization of products resulting from the research collaboration. Innate Pharma is eligible for up to €400m in development and commercial milestone payments as well as royalties on net sales.

Publications, posters and presentations